NDAORALTABLET
Approved
Feb 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORMINEST FE is an oral combined oral contraceptive tablet containing ethinyl estradiol and norethindrone, with added ferrous fumarate for iron supplementation during the hormone-free interval. It prevents pregnancy through hormonal suppression of ovulation and is indicated for contraception in women of reproductive age. The ferrous fumarate component helps offset menstrual iron loss.
LOE Approaching
Product is in mature/late-lifecycle phase with moderate competitive pressure (30/100), indicating a focus on defending market share rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NORMINEST FE offers limited career growth opportunities due to its mature, LOE-approaching status and minimal linked job openings. Career value lies primarily in managed markets defense, cost-containment strategy, and brand loyalty initiatives rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on NORMINEST FE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.